Based on these results, the FDA and EMA granted accelerated approval to pemigatinib, infigratinib, and futibatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic CCA with FGFR2 fusion or other rearrangements. Here, FGFR2 is linked to cholangiocarcinoma.